Oklahoma, J&J to wrap up first trial over opioid crisis
Sources told Reuters this month that Depomed was preparing to explore a sale and talks with potential buyers are expected to start shortly after a ruling on Nucynta, the company’s biggest dru A court ruled in Depomed Inc’s favor in a patent dispute over its opioid drug, Nucynta, a decision that could help pave the way for the drug maker to explore a sale.
Since 2000, some 6,000 Oklahomans have died from opioid overdoses, according to the state’s lawyers. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S.
Centers for Disease Control and Prevention.
The company also noted that it complied fully with strict U.S. Drug Enforcement Administration controls in importing poppy straw and other raw materials used to produce opioid anesthesia and pain medicines.
“Compared to many European and Asian developed nations, Australia places a high reliance on using opioids as first-line analgesia, despite evidence those countries with significantly lower reliance do not have poorer pain outcomes,” she said.
Recent court filings in New York and elsewhere contend that Sackler family members – who are worth an estimated $14 billion – were deeply involved in the business decisions that worsened the opioid epidemic.
Purdue reached a $270 million settlement with the state in March and Teva settled for $85 million in June. (Reporting by Nate Raymond in Boston; editing by Noeleen Walder and Steve Orlofsky)
Joe Rice, a lead plaintiffs attorney for municipalities in the federal litigation, said if the Oklahoma award were extrapolated to other states, it could mean an annual abatement cost of around $38 billion.
In its own filing, Johnson & Johnson – which divested both Tasmanian Alkaloids and Noramco in 2016 – argues that Oklahoma´s goal in seeking to unseal the documents is to “batter Oklahomans with sensationalistic headlines and to poison potential jurors” against its opioid unit, Janssen Pharmaceuticals, in advance of the May 28 trial.
Regeneron’s shares fell 3.6 percent, and were the biggest drag on the Nasdaq biotech index. Shares of Ophthotech Corp, If you loved this article and you would like to acquire more info pertaining to 100mg TAPENTADOL Overnight i implore you to visit the website. which is evaluating combinations of its experimental drug with Eylea or rival drugs, also fel Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
Thailand reported on Friday the first confirmed cases in Southeast Asia of microcephaly, a birth defect marked by small head size, linked to the Zika virus, a day after U.S. Confirmation that the Zika virus had caused microcephaly in Thailand is not likely to scare off large numbers of Chinese tourists due to jet in for holidays in the next week, tourists and industry operators said. officials recommended that pregnant women postpone travel to 11 countries in the region, including Thailand, because of Zik
Other drugmakers that sell opioid painkillers and are defending against similar lawsuits also rose after-hours, including Teva Pharmaceutical Industries Ltd up 2.6%, and Endo International Plc, up 1.4% higher.
The company also said Oklahoma failed to show that its products and activities had created a public nuisance. J&J said it will ask that the award be put on hold during an appeal process that could stretch into 2021.
“As a supplier, we did not have any role in the manufacturing, development, sales and marketing of other manufacturers´ finished products,” Janssen said in a statement emailed by a spokesman to Stateline.
Women with early-stage breast cancer may have fewer treatment complications and lower costs when they don’t get a mastectomy followed by reconstructive surgery, a U.S. In recent years, reconstruction following a mastectomy has become more widely available, contributing to a sharp increase in the number of women who opt for this treatment even when less aggressive alternatives may be just as effective, Buy TAPENTADOL UPS Delivery researchers note in the Journal of the National Cancer Institut
In holding J&J liable after a seven-week, non-jury trial, Judge Thad Balkman of Cleveland County District Court in Norman, Oklahoma, said the state proved that J&J’s misleading marketing and promotion of its Duragesic and Nucynta painkillers created a public nuisance.
Lawyers for Attorney General Mike Hunter and J&J are set to deliver closing arguments in state court in Norman, Oklahoma following six weeks of testimony from current and former J&J executives and victims of the epidemic.
The case is one of more than 2,000 actions by state and local governments accusing drug manufacturers of contributing to an epidemic linked to a record 47,600 opioid overdose deaths in 2017, according to the U.S.
NORMAN, Okla./BOSTON Aug 26 (Reuters) – An Oklahoma judge on Monday ordered Johnson & Johnson to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than investors had expected, driving up J&J’s shares.
Leave a Reply